gliadel 7.7 mg implant
mgi pharma gmbh - carmustine - implant - 7.7 milligram(s) - nitrosoureas; carmustine
carmustine 100 mg powder and solvent for concentrate for solution for infusion
tillomed pharma gmbh - carmustine - powder and solvent for concentrate for solution for infusion - 100 milligram(s) - nitrosoureas; carmustine
gliadel
mgi pharma limited - carmustine - implant - 7.7 milligram - carmustine
gliadel 7.7mg implant
clinigen healthcare ltd - carmustine - prolonged-release intralesional implant - 7.7mg
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastic agents - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
carmustine raz 100 mg
raz pharmaceutics ltd, israel - carmustine - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - carmustine - carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved agents in the following:• brain tumors - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors.• multiple myeloma - in combination with glucocorticoid such as prednisone. • hodgkin’s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.• non-hodgkin’s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
carmustine navinta 100 mg
mbi pharma ltd., israel - carmustine - powder and solvent for concentrate for solution for infusion - carmustine 100 mg/vial - carmustine - carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved agents in the following:• brain tumors - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors.• multiple myeloma - in combination with glucocorticoid such as prednisone. • hodgkin’s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.• non-hodgkin’s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy
carmustine obvius
k.s.kim international ltd - carmustine - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - carmustine - carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved agents in the following:• brain tumors - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors.• multiple myeloma - in combination with glucocorticoid such as prednisone. • hodgkin’s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.• non-hodgkin’s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
carmustine 100 mg powder and solvent for concentrate for solution for infusion
accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - antineoplastic agents
carmustine 100 mg powder and solvent for concentrate for solution for infusion
accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine